Connect with us

BUSINESS

GreenGro Technologies, Inc. (OTCMKTS:GRNH) Angling For A Piece Of The Cannabis Market’s Pie

Published

on

Data available reveals that California is the largest cannabis market in North America. This is so particularly after legalizing use of recreational cannabis. In this light, GreenGro Technologies, Inc. (OTCMKTS:GRNH) announced a solidification of the business in the State. In a press statement, the company lauded the move by the State calling it “historic.” The company expects a growth in demand for agricultural grow rooms. For that reason, the company expects growth in revenue.

Overhauling systems

In the statement, the company observes that the legislation could not have come at a better time. Per the statement, production is already underway for “sought-after strains of cannabis in the market today.” Through Genobreeding, the company will establish its name as “premier developers and distributors of cloned cannabis strains across the industry.”

Further, the statement revealed that it is overhauling its accounting team to bring its financial systems up to professional standards. This will facilitate the company’s intention to become a “fully-reporting SEC public entity.”

Commenting on the development, Chairman and CEO of GreenGro Technologies, Inc. (OTCMKTS: GRNH), Jim Haas said:

“We are very pleased with our ongoing progress in capturing a larger market share of the nation’s largest cannabis market following California’s latest reforms in its recreational cannabis laws. We look forward to the many opportunities that the State’s recreational market will present to us in 2018 and beyond and, as one of the first movers in the State, believe we are well-positioned to expand faster than ever in a market that is expected to grow to over $7 billion over the next few years.”

GreenGro Technologies, Inc. (OTCMKTS:GRNH) in strategic partnerships

To really exploit the benefits of the California market, the company announced partnerships with local companies. In a press statement, the partnership aims to provide “testing and quality control services” that will increase cash flow. The partnership includes D5 Partners, Inc., County Line Energy Corp., and Vertical Hydrogarden, a GreenGro Technologies, Inc. (OTCMKTS:GRNH) subsidiary. As per the statement, Vertical Hydrogarden will “acquire future distribution rights to Grow Box 5000 products.”

According to the GreenGro Technologies CEO, working with D5 Partners will help the partners reach maximum cannabis growing yields. According to the statement, D5 Partners will provide technology that will facilitate the growing yields in home environments.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

The Launch of Big Bag o’ Buds; a Dried Flower in 28g Value Format by Organigram Holdings Inc (NASDAQ: OGI)

Published

on

The founding of Organigram Holdings Inc (NASDAQ: OGI) in 2013 was one of the milestones for the Cannabis industry. Today, the Company, the first medical cannabis provider, is focused on developing international business partnerships to extend its global footprint. 

It has a wide range of products under its sleeves, including adult-use recreational cannabis brands.

One of the most notable brands is Bag o’ Buds, which was recently launched. The product features a line-up of dried flower products with a roster of well-known genetics. The product, which comes in a 28g format, offers a minimum of 17% THC. The rich cultivar selection includes intense, Sativa-leaning sour, spicy notes from the cultivar’s Kush undertones and Ultra Sour. 

“Without a doubt, Big Bag o’ Buds… offers Canadian consumers a continuous pipeline of new cultivars reflecting our team’s ongoing search for and development of new terpene profiles and phenotypic expressions,” the Senior Vice President of Sales and Commercial Operations at Organigram, Tim Emberg, reported. 

Some of the benefits of the Big Bag o’ Buds strain include the fact that it optimizes each cultivar’s flavor and can customize its light and plant density to enhance the output of each plant. 

The Appointment of a Marketing Expert

Megan McCrae has joined Organigram Holdings Inc. in the position of Senior Vice President of Marketing and Communications. 

The appointment is timely when the Canadian-based Company strides with its brand and product strategy, brand and portfolio management, innovation, and digital strategy. 

Given her previous roles as the Board Chair on the Cannabis Council of Canada, Ms. McCrae has over the years become a cannabis industry veteran. Hence, the new position suites her best. She has also worked with Japan Tobacco International, a major global tobacco company, and industry leaders and regulators. 

Organigram’s Executive Chair, Peter Amirault, says that Megan’s tremendous marketing expertise will be instrumental in establishing theCompany’ss roadmap for the future and the Company’s emerging portfolio of brands and products. 

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

A Failure-to-File Cease Trade Order against Claritas Pharmaceuticals Inc (OTCMKTS: KALTF) Revoked

Published

on

Earlier in the year, Claritas Pharmaceuticals Inc (OTCMKTS: KALTF) found itself on the receiving end following the Failure-to-File Cease Trade Order (“CTO”). The British Columbia Securities Commission (the “BCSC”), in conjunction with Ontario Securities Commission (the “OSC”), issued the order on June 22, 2020. The Company had failed to meet the prescribed deadlines for filing its annual financial statements for the year ending December 31, 2019, resulting in the suspended trading of its common shares.

The BCSC and the OSC Grants Full Revocation of the Failure-to-File Cease Trade Order

Kalytera Therapeutics’ commitment to developing new treatments for a variety of diseases and disorders is prevalent. The Company’s focus is on using its expertise to find solutions, dramatically improving people’s lives. Despite the earlier tribulations, the Company has reported the revocation of the trade order. 

On November 4, 2020, the Company applied to the BCSC and the OSC to have the FFCTO entirely revoked. Another application followed this to TSXV on October 30, 2020, to remove its suspension and allow trading of the Company’s shares. But it is until January 22, 2021, when this was granted. The need for approval by the TSXV may have caused a more extended waiting period, but the good news is that the reinstatement review is now complete.

Kalytera’s License Agreement with Salzman Group, Inc. 

Through an R-107 License Agreement, Kalytera has obtained an exclusive worldwide license from Salzman Group, Inc. The agreement obligates Kalytera to develop, distribute, import, export and commercialize R-107, a treatment of coronavirus and COVID-19 infection. The liquid treatment is administered orally in a capsule, or nasally or by intramuscular injection. And in sealing this deal, Kalytera will part with a license fee of USD 1.2 million.

Kalytera is already enjoying an exclusive, worldwide License Agreement, an exclusive, worldwide license obtained from Beetlebung Pharma, Ltd. This was on March 20, 2018. Kalytera has worked with this molecule to demonstrate its potential in developing a potent, oral analgesic to treat pain. 

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) Enters into a Definitive Agreement to Acquire GW Pharmaceuticals Plc (OTCMKTS: GWPRF)

Published

on

As a global biopharmaceutical company whose purpose is to provide life-changing medicines for people with serious diseases, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is constantly building on its portfolio of marketed medicines. The Company is also not new to collaborations, given that it is serving patients in nearly 75 countries. In the recent past, the Dublin, Ireland-based organization has acquired GW Pharmaceuticals Plc (OTCMKTS: GWPRF), a global biopharma leader in developing and commercializing cannabinoid-based prescription medicines. 

The combined Company will be a leader in neuroscience and will give it an upgrade position to maximize the value of its diversified portfolio. Meanwhile, through its chairman and chief executive officer, Bruce Cozadd, Jazz Pharmaceuticals has expressed contentment and an expectation of marking a transformative milestone in creating an innovative and high-growth commercial and operational footprint. 

“…The addition of GW further diversifies our commercial portfolio and innovative pipeline with therapies that are complementary to our existing business, including Epidiolex, a high-growth commercial product with near-term blockbuster potential…’’ Cozadd emphasized. 

The European Commission Approves EPIDYOLEX® (cannabidiol) From GW Pharmaceuticals.

It is a rare genetic condition that has an estimated prevalence in the EU of 10 in 100,000. Tuberous Sclerosis Complex (TSC) often occurs in the first year of life, with patients initially suffering from seizures or infantile spasms. Some of its symptoms include benign tumors, which grow in the body’s vital organs such as lungs, heart, and kidneys. 

However, the European Commission of EPIDYOLEX® (cannabidiol) approval is likely to treat seizures associated with TSC. Following the demonstrated efficacy and safety profile from Phase 3 of EPIDYOLEX will relieve families of patients affected by this debilitating disease. It is also a reliever for physicians managing seizures associated with TSC. 

The eligibility is for anyone of two years and above. According to Justin Gover, GW’s Chief Executive Officer, they are looking forward to making it available to patients across Europe as quickly as possible. 

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories